



**NOVILYTIC**

THE CANARY IN THE FERMENTOR

# TURN YOUR LC INTO A PROTEOFORM METER

## PROTEOMETER-L STARTER KIT

The Proteometer Kit transforms any LC into an analytical system capable of identifying and quantifying titer and relative aggregate content in crude culture filtrate in <10 minutes, without sample preparation.

This plug-and-play solution provides savings of over \$100,000 per day by eliminating the hours of sample preparation traditionally required for molecular analysis.<sup>1</sup>

At-line Applications:

- High Throughput Screening
- Clone Selection
- Product Characterization
- PR&D and Manufacturing


## FEATURES & BENEFITS

- Direct analysis from CFF
- Includes all components for titer & aggregate analysis of mAbs
- <10-minute structural analysis
- Allows for multiplexing, unlike traditional ELISA analysis
- Works with existing LCs



## KIT COMPONENTS / FEATURES


- Proteometer-L Reactor
- Proteometer-L Reagent
- Proteometer-L Buffer
- Proteometer-L Reconstitution Reagent
- Instructions for use




<sup>1</sup> JAMA, March 3, 2020; Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018; Olivier J. Wouters, PhD1; Martin McKee, MD, DSc2; Jeroen Luyten, PhD3; Average cost range, 10-year development

# SCIENTIFIC BENEFITS

- No sample purification required
- mAb titer and relative aggregate content in one easy-to-use assay
- Linear response from 0.5-80µg mAb (response range may vary per instrument)
- Very small sample mass required – 0.5-10µg
- No Mass Spec required



## Titer and Aggregate Analysis of Rituximab (IgG1 Kappa).




*"The Proteometer is expected to play a central role in the development and commercialization of next-level biological manufacturing control strategies. The integration of complementary bioprocess analytical data facilitates decision-making through a powerful link between the manufacturing space and the QC laboratory."*

Eugene L. Inman, Ph.D.

*"Novilytic's Proteometer is a disruptive breakthrough that finally solves the FDA's requirement to continuously monitor t-mAb proteoforms during fermentation. The approach improves product safety, reduces COPQ and post release testing, and paves the way for real-time product release, reducing inventory costs."*

Martin Long, BSc. Performance Validation, Inc.  
President & CEO

## Robust over 1,000 injections



SCAN ME